Novo Nordisk A/S (ADR) (NYSE:NVO)

CAPS Rating: 4 out of 5

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals.

Recs

0
Player Avatar kevinlar61 (55.33) Submitted: 7/1/2010 3:39:13 PM : Outperform Start Price: $79.43 NVO Score: +48.48

Great drugs in pipeline

Report this Post Reply

Featured Broker Partners


Advertisement